Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | EIF4E | P06730 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989121 | 0.90 | EIF4E (0.47) | ALDH1A1TSHRMAPK1KMT2AEIF4E | |
| SCHEMBL40329 | 0.84 | ALDH1A1 (0.59) | ALDH1A1TSHRMAPK1SMN1; SMN2KMT2A | |
| SCHEMBL9193556 | 0.80 | DTYMK (0.46) | ALDH1A1TSHRMAPK1KMT2AMEN1 | |
| SCHEMBL989123 | 0.79 | TSHR (0.40) | ALDH1A1TSHRMAPK1SMN1; SMN2KMT2A | |
| SCHEMBL9354317 | 0.76 | EIF4E (0.54) | ALDH1A1TSHRMAPK1SMN1; SMN2EIF4E | |
| SCHEMBL9354304 | 0.76 | EIF4E (0.54) | ALDH1A1TSHRMAPK1SMN1; SMN2EIF4E | |
| Water SCHEMBL11042053 | 0.75 | TDP1 (0.51) | ALDH1A1TSHRKMT2AEIF4EGAA | |
| SCHEMBL3030242 | 0.75 | PDK1 (0.43) | ALDH1A1TSHRMAPK1SMN1; SMN2KMT2A | |
| SCHEMBL1667732 | 0.74 | TDP1 (0.56) | ALDH1A1TSHRMAPK1SMN1; SMN2KMT2A | |
| SCHEMBL29485896 | 0.73 | MAPK1 (0.64) | ALDH1A1TSHRMAPK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454258-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | Merck Patent GmbH (DE) | 2012-05-23 | — | — | EP | disclosed |
| US-20120115852-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-10 | — | — | US | disclosed |
| WO-2011006569-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115852-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | ENPP2, HAX1, SERPINH1 | ALDH1A1 4192/4885TSHR 317/4885MAPK1 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.